Valuation : Pyxis Oncology, Inc.

Market Cap 273M 235M 221M 202M 377M 26.08B 380M 2.64B 1.01B 13.23B 1.02B 1B 42.01B P/E 2026 *
-2.67x
P/E 2027 * -3.02x
Enterprise Value 273M 235M 221M 202M 377M 26.08B 380M 2.64B 1.01B 13.23B 1.02B 1B 42.01B EV / Sales 2026 *
14,030x
EV / Sales 2027 * 98.2x
Free-Float
86.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Pyxis Oncology, Inc.

1 day-3.25%
1 week-8.27%
Current month+0.93%
1 month-14.62%
3 months+95.81%
6 months+110.97%
Current year+184.35%
1 week 3.13
Extreme 3.132
4.15
1 month 2.72
Extreme 2.72
4.15
Current year 1.13
Extreme 1.13
4.15
1 year 1.03
Extreme 1.03
5.55
3 years 0.83
Extreme 0.8332
6.85
5 years 0.83
Extreme 0.8332
19
10 years 0.83
Extreme 0.8332
19
Manager TitleAgeSince
Chief Executive Officer 57 2026-02-02
Director of Finance/CFO 45 2025-06-30
Chief Tech/Sci/R&D Officer - 2022-11-30
Director TitleAgeSince
Chairman 57 2018-04-30
Chairman 57 2026-09-03
Director/Board Member 61 2021-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Free

Chief Executive Officer

2,503,050 3.0010%
8/20/26 Free

Director

46,000 0.0726%
8/12/26 Free

Chief Executive Officer

250,956 0.3961%
Change 5-day change 1-year change 3-year change Capi.($)
-3.25%-8.27%+74.87%+53.52% 282M
-0.25%-1.36%+44.08%+102.76% 68.52B
-1.09%-6.20%+30.50%+76.56% 62.88B
-1.18%+0.47%-12.78%+384.69% 28.13B
-1.47%-4.84%+30.00%+9.60% 25.56B
-1.76%-6.30%-4.55%-19.75% 24.65B
-2.39%-5.19%+17.75%-20.95% 19.81B
-1.86%-2.22%+202.03%+353.89% 17.69B
-2.07%-5.07%-5.42%+494.88% 14.66B
-1.54%-2.88%+52.33%+159.75% 14.45B
Average -1.69%-2.63%+42.88%+159.49% 27.66B
Weighted average by Cap. -1.21%-2.19%+35.63%+136.85%

Financials

2026 *2027 *
Net sales 19.44K 16.72K 15.77K 14.37K 26.86K 1.86M 27.11K 188K 72.3K 943K 73K 71.41K 2.99M 2.78M 2.39M 2.25M 2.05M 3.84M 266M 3.87M 26.84M 10.33M 135M 10.43M 10.2M 428M
Net income -94.39M -81.18M -76.59M -69.77M -130M -9.02B -132M -912M -351M -4.58B -354M -347M -14.54B -114M -98.07M -92.53M -84.3M -158M -10.9B -159M -1.1B -424M -5.53B -428M -419M -17.56B
Net Debt - -
Logo Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Employees
56
Date Price Change Volume
26-09-10 US$3.270 -3.25% 742,141
26-09-09 US$3.380 -13.11% 4,345,259
26-09-08 US$3.890 0.00% 1,375,571
26-09-04 US$3.890 +9.12% 2,230,891
26-09-03 US$3.565 -4.93% 812,184
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.270USD
Average target price
8.444USD
Spread / Average Target
+158.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYXS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!